Bright Minds Biosciences Inc.

NASDAQ:DRUG

Biotechnology

Healthcare
$20.76 +1.04%

+$0.62 today

Market cap
$204.78M
Beta
-0.11
P/E (TTM)
-29.8
EPS (TTM)
-$2.87
52W Low $23.18High $123.75

Volume 0.14M

Average 0.27M

DRUG Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Bright Minds Biosciences Inc.NASDAQ: DRUG

Research & Development · Q2 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of CA$13.27M rose 417.5% year over year, behind the +663.6% change in trailing-twelve-month research & development. Sequentially, it rose 134.3% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +417.5% toward the trailing-twelve-month pace of +663.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$13.27M+134.3% QoQ
Last fiscal yearSep 2025
CA$11.08M+839.4% YoY
LTMMar 2026
CA$26.4M+663.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+417.5%——
1 year+839.4%——
3-year CAGR-3.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
11.08M CAD
Year-over-year change
+839.4%
4-year CAGR
+15.1%

Research & Development vs competitors

How DRUG compares with its peers on the latest reported figures

No competitor Research & Development figures are available to compare.

Income Statement

CAD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.31M12.18M5M1.18M11.08M
Selling, General & Admin2.31M2.55M2.2M1.45M2.57M
Operating Expenses8.62M14.98M7.39M2.82M13.94M
Depreciation & Amortization8.62M6.04K72.45K73.36K76.87K
EBITDA(27.64K)(14.96M)(7.3M)(2.73M)(12.15M)
EBITDA Margin—————
Operating Income(8.62M)(14.98M)(7.39M)(2.82M)(13.94M)
Operating Margin—————
Interest Income00030.13K1.52M
Interest Expense00000
Other Income / Expenses(27.64K)10.15K14.19K20.82K1.71M
Income Before Tax(8.65M)(14.96M)(7.37M)(2.8M)(12.23M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(8.65M)(14.96M)(7.37M)(2.8M)(12.23M)
Net Margin—————
EPS (Basic)(4.74)(6.15)(1.98)(0.65)(1.78)
EPS (Diluted)(4.74)(6.15)(1.98)(0.65)(1.78)
Weighted Avg Shares1.79M2.47M3.72M4.31M6.88M
Weighted Avg Shares (Diluted)1.79M2.47M3.72M4.31M6.88M

Bright Minds Biosciences Inc.

NASDAQ:DRUG

Intrinsic Alpha fair value

Locked

Current Price

$20.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.